Original link: https://kaopubear.top/blog/2022-12-15-mammaprint-intro-from-nature-to-product/
The pleasure of reading literature usually lies outside the literature. Connect seemingly unrelated content through clues in the literature and off-site information. If you happen to answer the questions that have been lingering in your mind for a long time, it will be a rare “Paper Aha Moment”.
What is the fun of reading boring literature? My feeling is that this kind of pleasure often comes from outside the literature , a kind of satisfaction of curiosity and the pleasure brought about by the association of fragmentary information in the mind .
As I wrote in the previous article , I mentioned four parts when summarizing my learning methods for tumor NGS-related content.
- Learn about various types of cancer through clinical guidelines
- Subject-based literature integration and interpretation
- Top companies/products for precise tumor therapy at home and abroad
- Well-known institutions/hospitals for precise tumor treatment at home and abroad
Recently, when preparing the content of Xiong Yan Xiong Yu’s membership plan, I found a particularly interesting example that I can share with you. In addition to showing how the above are related, it may also explain why the pleasure of reading literature usually lies outside the literature .
cause
The cause of the matter was that when I sorted out the latest review of nature reviews drug discovery a few days ago, I planned to add some author information.
The title of this article is Rational combinations of targeted cancer therapies: background, advances and challenges. If you are interested, you can also read it.
The author of the article is Professor Jin Haojie from Shanghai Jiaotong University. According to public information, he visited and conducted collaborative research at the National Cancer Institute of the Netherlands from 2017 to 2021. Professor (also a consultant professor of Shanghai Jiao Tong University).
Bernards’ research results are very rich, such as the co-discoverer of the first tumor suppressor gene Rb, he has developed shRNA vectors for gene silencing in animal cells, and discovered multiple important molecular mechanisms of tumor drug resistance and potential combination therapies through this technology Strategy, presumably this is why there is the review I mentioned above.
It stands to reason that if you find the basic information of the author, you can continue with other content, but curiosity drove me to read more. So I sorted out such a story from the Nature paper in 2002 to the revenue of 100 million yuan in 2022.
In this story, there are multiple roles of well-known professors, the transaction and cooperation of domestic and foreign tumor NGS companies, and the long process from scientific research to clinical transformation.
One method leads to two top publication papers
In 2020, at the 157th annual meeting of the National Academy of Sciences, a professor from the Netherlands was selected as a member of the National Academy of Sciences to recognize and recognize his outstanding contributions in the field of tumor research over the past 30 years. His name is René Bernards.
If you look at the two highly cited papers by Bernards in the past few decades, you will find that they were published in Nature and NEJM in 2002.
Nature article published in 2002
NEJM article from late 2002
It is not difficult to see that one thing is being said: a gene set that can be expressed to predict patient survival has been found in breast cancer.
In the first published paper, the authors’ team identified a gene expression profile of dozens of genes associated with the risk of early distant metastasis in patients with node-negative breast cancer.
In the second study, the author’s team tested and analyzed 295 patients treated at the Hospital of the Netherlands Cancer Institute, proving that this indicator can be used to guide the prognosis of patient treatment. On the one hand, this method can find more low-risk patients than the previous traditional classification indicators, and at the same time, it can also carry out accurate classification on the basis of the original classification.
If the metastatic ability of breast cancer can be tested and diagnosed at an early stage of tumor development, it will naturally improve the selection of patients who benefit from adjuvant therapy, thereby reducing the rate of overtreatment and undertreatment.
Two papers lead to a diagnostic product
The beautiful research conclusion must have given everyone great encouragement and confidence.
On July 10, 2003, a start-up company called Agendia was established in the Netherlands, and Bernards was the co-founder and Chief Scientific Officer.
Today, on Agendia’s official website, they proudly present themselves as the only molecular diagnostics company focused exclusively on breast cancer.
Less than a year after its founding, Agendia launched a flagship product in Europe that monitors the risk of breast cancer recurrence and later entered the United States. In 2007, it became the first FDA-cleared IVDMIA (In Vitro Diagnostic Multivariate Index Assay), and has since received 6 additional FDA clearances.
As shown in the materials of the year, this product called MammaPrint is the well-known breast cancer 70 gene detection in the molecular diagnosis industry. The prototype of this 70-gene expression profiling product comes from the two papers published in Nature and NEJM in 2002.
A product brings billion-level revenue to Chinese companies
Turning back to the domestic market, on November 17, 2014, a tumor diagnosis company named Zhenhe Technology was established in Wuxi.
In 2018, Zhenhe Technology and Agendia signed an exclusive sales agreement for this product, officially introduced this product in China and named it Maprun.
In November 2020, after revising the agreement with Agendia, Zhenhe has the exclusive commercialization rights of MammaPrint in China. In exchange, a commitment to purchase a minimum quantity of products for sale and distribution in China.
When commodities come in, it is natural to promote the update of diagnosis and treatment guidelines.
MammaPrint has also been recommended in the 2021 edition of the CSCO Breast Cancer Diagnosis and Treatment Guidelines (see notes)
As a commercial product, you naturally care about its domestic sales.
In 2022, the data disclosed in the Zhenhe Hong Kong stock IPO prospectus shows that in 2020, 2021 and the first half of 2022, the sales revenue of MammaPrint will be approximately 35 million, 46 million and 19 million respectively.
In other words, in the past two and a half years, MammaPrint has brought the Chinese company 100 million-level revenue.
write at the end
As the originator product of breast cancer recurrence detection, the evidence-based process of MammaPrint clinical research is worthy of a separate introduction in the future. (emmm~ will be presented in the future Xiongyan Xiongyu membership plan, welcome to scan the code to subscribe, and receive updates as soon as possible)
Ever since I came into contact with the tumor biomedical industry, I have always had a curiosity:
When a product/drug appears in front of patients, what kind of process and how long does it need to go through.
With the background research of the authors of this unrelated review, from the literature to the author, from the author to the laboratory and previous research, from clinical research to clinical guidelines and IPO prospectus.
In this way, there is actually an outline in my mind, Aha, it turned out to be like this.
Back to the story itself.
From the Netherlands, the United States to China, Nature and NEJM published papers to the establishment of Agendia, from the academician of the American Academy of Sciences to serving as a consulting professor at Jiaotong University, from the launch of MammaPrint products, FDA approval, and domestic introduction to achieve 100 million-level revenue in more than two years.
From 2002 to 2022, in 20 years, we have seen the rough process from scientific exploration to clinical research to product commercialization, and we have also watched the wonderful life of Bernards boss.
As stated at the beginning of the article.
For me, the pleasure of reading literature often lies outside the literature. In this seemingly boring thing, you can also find your own fun by opening your gossip heart.
The author of this article : bear who thinks about problems
Copyright statement : Unless otherwise stated, all articles on this blog are licensed under the Creative Commons Attribution-Non-Commercial Use-No Derivatives 4.0 International License Agreement (CC BY-NC-ND 4.0) .
If you are interested in this article, please subscribe to my “Xiong Yan Xiong Yu” member newsletter via email or WeChat. I will share with you the latest industry research progress in the field of tumor biomedicine and what I think and learn. If you want , click this link to subscribe for free.
This article is transferred from: https://kaopubear.top/blog/2022-12-15-mammaprint-intro-from-nature-to-product/
This site is only for collection, and the copyright belongs to the original author.